newsfilter
← Latest News
GlobeNewswire·

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RNXT
  • RenovoRx, Inc. (NASDAQ: RNXT) appointed Professor Thierry de Baère, MD, PhD, to its Scientific Advisory Board (SAB) on Oct. 09, 2025.
  • Professor de Baère serves as Head of the Interventional Radiology Unit at Gustave Roussy Cancer Centre & University Paris-Saclay in France.
  • His expertise in minimally invasive therapies supports RenovoRx's Trans-Arterial Micro-Perfusion (TAMP™) platform enabled by the FDA-cleared RenovoCath device.
  • The TAMP™ technology is designed to optimize targeted drug delivery near tumor sites to potentially reduce systemic toxicities.
  • Professor de Baère holds over 400 peer-reviewed publications with 22,000+ citations & has received awards including the 2019 CIRSE Gold Medal & 2020 CIRSE Innovation Award.
  • RenovoRx is evaluating its drug-device combination candidate, intra-arterial gemcitabine (IAG), in the Phase III TIGeR-PaC trial for pancreatic & bile duct cancers.
  • IAG has received Orphan Drug Designation from the FDA for seven years of market exclusivity upon approval.
  • The company announced its first commercial purchase orders for RenovoCath in Dec. 2024, with repeat orders from high-volume National Cancer Institute-designated centers.
  • RenovoRx continues to explore revenue-generating activities for RenovoCath either independently or through a medical device commercial partner.
  • The press release includes a cautionary note regarding forward-looking statements related to clinical trials, commercialization, & regulatory approvals.